Check out the latest updates from Cinclus Pharma
Highlights from the 2024 Annual Report: Market overview. 24-hour acid control is the most important characteristic to differentiate an acid-suppressive drug and to create optimal healing conditions.
Read more
Highlights from the 2024 Annual Report: Market overview. Significant proportion of severe eGERD patients treated by Gastroenterologists remain unhealed with PPI treatment.
Read more
Highlights from the 2024 Annual Report: Interview with the founders. Cinclus Pharma, founded by a team of experts with deep roots in the pharmaceutical industry, is on a mission to bring an effective GERD treatment, linaprazan glurate, to the market. Building on groundbreaking work done at AstraZeneca.
Read more